Correlation Between Inhibikase Therapeutics and DiaMedica Therapeutics

Can any of the company-specific risk be diversified away by investing in both Inhibikase Therapeutics and DiaMedica Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibikase Therapeutics and DiaMedica Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Inhibikase Therapeutics and DiaMedica Therapeutics, you can compare the effects of market volatilities on Inhibikase Therapeutics and DiaMedica Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibikase Therapeutics with a short position of DiaMedica Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibikase Therapeutics and DiaMedica Therapeutics.

Diversification Opportunities for Inhibikase Therapeutics and DiaMedica Therapeutics

0.31

Correlation Coefficient

Inhibikase Therapeutics  DiaMedica Therapeutics

Weak diversification

The 3 months correlation between Inhibikase and DiaMedica is 0.31. Overlapping area represents the amount of risk that can be diversified away by holding Inhibikase Therapeutics and DiaMedica Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on DiaMedica Therapeutics and Inhibikase Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibikase Therapeutics are associated (or correlated) with DiaMedica Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of DiaMedica Therapeutics has no effect on the direction of Inhibikase Therapeutics i.e., Inhibikase Therapeutics and DiaMedica Therapeutics go up and down completely randomly.

Pair Corralation between Inhibikase Therapeutics and DiaMedica Therapeutics

Considering the 90-day investment horizon Inhibikase Therapeutics is expected to generate 2.07 times more return on investment than DiaMedica Therapeutics. However, Inhibikase Therapeutics is 2.07 times more volatile than DiaMedica Therapeutics. It trades about 0.2 of its potential returns per unit of risk. DiaMedica Therapeutics is currently generating about 0.16 per unit of risk. If you would invest  134.00  in Inhibikase Therapeutics on August 31, 2024 and sell it today you would earn a total of  139.00  from holding Inhibikase Therapeutics or generate 103.73% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Inhibikase Therapeutics  vs.  DiaMedica Therapeutics

Inhibikase Therapeutics

Risk-Adjusted Performance

15 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Inhibikase Therapeutics are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady forward-looking signals, Inhibikase Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

DiaMedica Therapeutics

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in DiaMedica Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain basic indicators, DiaMedica Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Inhibikase Therapeutics and DiaMedica Therapeutics

The main advantage of trading using opposite Inhibikase Therapeutics and DiaMedica Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibikase Therapeutics position performs unexpectedly, DiaMedica Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DiaMedica Therapeutics will offset losses from the drop in DiaMedica Therapeutics' long position.

The idea behind Inhibikase Therapeutics and DiaMedica Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.